Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

3.570 -0.110 (-2.99%)
Streaming Delayed Price Updated: 11:29 AM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years
Via FinancialNewsMedia
Topics Law Enforcement
Psyched: First Psychedelics ETF Comes To The US, Bills Move Forward In Texas, California and New York
Psychedelics ETFs Are Gaining Traction Defiance ETFs launched the “Next Gen Altered Experience ETF,” the ... 
Via Benzinga
Psychedelic Drug Stocks: A Big Healthcare Footprint At A Small Price
Fuelled by hundreds of millions in startup capital, psychedelic drug companies are powering a Revolution in healthcare. But with the sector currently in a trough, investors can still enter at... 
Via Talk Markets
Meet PsyBio, A Company Producing Psilocybin From Genetically-Modified Bacteria
As psychedelics draw closer to legalization, companies in the industry have yet to figure out the most efficient and cost-effective way of producin... 
Via Benzinga
Cannabis Countdown: Top 10 Marijuana and Psychedelics Industry News Stories of the Week
Welcome to the Cannabis... 
Via Benzinga
Topics Cannabis
Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week
Welcome to the Cannabis... 
Via Benzinga
Topics Cannabis
How Risky Are Psychedelic Stocks?
Public and private companies are studying the use of psilocybin ("magic mushrooms") to treat severe depression, and MDMA (ecstasy) to treat post-traumatic stress disorder. 
Via The Motley Fool
Topics Cannabis
Is Compass Pathways a Buy?
The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic mushrooms." Will this be a money-maker? 
Via The Motley Fool
Topics Cannabis Law Enforcement
Can Psychedelics Actually Cure Depression and PTSD?
There is now data suggesting that magic mushrooms and ecstasy -- combined with talk therapy -- may help people with severe depression and post-traumatic stress disorder. 
Via The Motley Fool
Topics Cannabis
Psychedelic Drug Developer Sets Sights On This Age-Old Hallucinogen
MindMed stock fell after it said a Swiss ethics committee cleared it to begin a study on the effects of the hallucinogen mescaline. 
Via Investor's Business Daily
Compass Pathways Offers Chance on Exploratory Mental Health Treatments
Over the past year, CMPS stock has been going nowhere fast. However, there's been recent progress in advancing psilocybin-assisted therapy. 
Via InvestorPlace
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa... 
Via Benzinga
Compass Releases Q1 Earnings: Strong Cash Position For Psilocybin R&D Efforts
Compass Pathways (NASDAQ:CMPS), a company researching psyc... 
Via Benzinga
COMPASS Pathways plc (CMPS) Q1 2021 Earnings Call Transcript
CMPS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing
Via FinancialNewsMedia
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week
Welcome to the Cannabis Countdo... 
Via Benzinga
Topics Cannabis
Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders
Concentration of ownership in psychedelic drug stocks has reached a new extreme. We explain how and why we don't see this trend as being sustainable. 
Via Talk Markets
The Next Psychedelic Stock To Uplist On The Nasdaq?
As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next? 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021
Upgrades For CEVA Inc (NASDAQ:CEVA), Barclays upgraded the previous rating of Equal-Weight to Overweight. For the first quarter, CEVA had an EPS of $0.01, compared to year... 
Via Benzinga
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week 
Via Benzinga
Topics Cannabis
Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic
Via FinancialNewsMedia
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Akari Therapeutics (NASDAQ:AKTX) stock moved upwards by 14.1% to $2.67 during Wednesday's pre-market session. The company's market cap stands at $102.7... 
Via Benzinga
Second-Chance Buying Opportunity With Psychedelic Stock Warrants
Psychedelic stock warrants delivered epic returns for investors in the big rally in these stocks in 2020. After the pullback in 2021, some of these warrants are again looking attractive. 
Via Talk Markets
MindMed Stock Climbs In Nasdaq Debut As Psychedelics Follow Pot's Path To Mainstream
MindMed stock rose in its Nasdaq listing debut on Tuesday, making it the latest psychedelic drug developer to land on a major U.S. exchange. 
Via Investor's Business Daily
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week 
Via Benzinga
Topics Cannabis
Majority Of Pure-Play Psychedelic Drug Stocks Went Up Last Week
41 psychedelic drug stocks trade on the various North American stock exchanges and in the past week 24 went up, 12 went down and 5 had no change in price. 
Via Talk Markets
Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading
Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after ... 
Via Benzinga
With Number Of Depression Cases Rising, Psilocybin Medicines Are Being Rapidly Accepted
Via FinancialNewsMedia
Déjà Vu: 2021 Slump In Psychedelic Stocks Mirrors 2020
Charts for most psychedelic drug stocks look terrible in recent weeks. The same was true in the summer of 2020 -- immediately before these stocks exploded higher. Deja vu? 
Via Talk Markets
Psychedelic Stocks: Atai Life Sciences IPO Seeks To Raise $100 Million
Atai Life Sciences hopes to raise $100 million in an initial public offering, as other psychedelic stocks seek investor cash. 
Via Investor's Business Daily
Topics Initial Public Offering
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.